Yale researchers are using chemical “chameleons” to sneak up on drug-resistant brain tumors.
A Yale Cancer Center team has synthesized a compound, KL-50, that they say selectively targets drug-resistant glioblastomas while leaving healthy tissue alone.
Yale scientists say KL-50, their lead “chameleon” compound, effectively targets tumors without harming healthy surrounding tissue.
Leave a reply